Trial Profile
Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs Obrindatamab (Primary)
- Indications Advanced breast cancer; Bladder cancer; Carcinoma; Colon cancer; Head and neck cancer; Malignant melanoma; Malignant-mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Thyroid cancer; Triple negative breast cancer; Urogenital cancer
- Focus Adverse reactions; First in man
- Sponsors MacroGenics
- 02 Mar 2020 Status changed from active, no longer recruiting to discontinued.
- 12 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 04 Feb 2019 Planned number of patients changed from 114 to 200.